BackVivoryon Therapeutics N.V. Overview

Vivoryon Therapeutics N.V. Total Current Liabilities

Latest total current liabilities for VVY.AS: $690K.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$688000.00
↓ 47.04% YoYΔ $-611000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Vivoryon Therapeutics N.V. Total Current Liabilities History

Loading

Vivoryon Therapeutics N.V. vs. peers: Total Current Liabilities Comparison

Loading

Vivoryon Therapeutics N.V. Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Vivoryon Therapeutics N.V. (VVY.AS) FAQ

Vivoryon Therapeutics N.V.'s total current liabilities stands at $690K as of June 2026. That compares with $1.3M in the prior-year period — down 47.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Vivoryon Therapeutics N.V. reported $690K in total current liabilities versus $1.3M a year earlier — a 47.0% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $1.3M in the prior-year period — down 47.0% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Vivoryon Therapeutics N.V.'s total current liabilities evolved across reporting periods, while the comparison chart places VVY.AS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. Vivoryon Therapeutics N.V.'s reading of $690K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.

Questions & Answers